An Open-Label, Parallel-Group, Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal Hepatic Function or With Moderately Impaired Hepatic Function (Child-Pugh Class B)
Latest Information Update: 30 Jul 2021
At a glance
- Drugs Padsevonil (Primary)
- Indications Epilepsy
- Focus Pharmacokinetics
- Acronyms Child-Pugh Class B
- Sponsors UCB Biopharma
Most Recent Events
- 19 Jun 2020 Status changed from suspended to discontinued.
- 17 Apr 2020 Status changed from recruiting to suspended.
- 07 Nov 2019 Planned End Date changed from 1 Jun 2020 to 1 Jul 2020.